Not rendering correctly? View this email as a web page here.

- March 2018 -


The California Life Sciences Institute Hosts First CLSI Women Life Science Executives Dinner

Read More


  • Big3Bio interviews Inflammatix (FAST Fall 2017): Interrogating the Immune System for Diagnosing Infection | Read More
  • SciBac (FAST Fall 2016) selected to present and compete at Partnering for Growth’s Biotech Innovation Showcase on March 20 | More Info
  • Cairn Biosciences (FAST Fall 2015) featured in the San Francisco Business Times on the importance of Mission Bay’s incubators and the value they bring to entrepreneurs for getting access to world-class facilities | Read More
  • GigaGen (FAST Spring 2015) presented methods for rapid immune-oncology antibody discovery at 2018 Keystone Symposia on Antibodies as Drugs | Read More

About FAST Advisory Program

The FAST Advisory Program provides select entrepreneurs with intensive team review and coaching to perfect their business model, product development plans, and to build a compelling commercialization strategy. Experienced entrepreneurs, product and business experts (which may include clinical development, regulatory, reimbursement and business development specialists) will advise selected Fellows during a twelve-week program, culminating in a Final FAST Showcase to a broad audience that includes potential investors and partners.

For information on the FAST program, contact Steve Karp at or Julie Harness at

Upcoming Events & Key Dates
3/15 MedTech Innovator 2018: JLABS Pitch Event, JLabs, South San Francisco Register Here
3/15 Application deadline for IndieBio Summer 2018 Class Apply Here
3/21 IndieBio: The Future of Health is Personal, San Francisco, CA  Register Here
3/21 UCSF Entrepreneurship Center Speaker Series: What’s the Latest in Digital Health Investment? UCSF Mission Bay Register Here
3/27 Digital Beauty: Beyond the jar – It is more than skin deep, JLabs South San Francisco  Register Here
3/29 Meet with Frazier Healthcare Partners, JLabs, South San Francisco  Register Here
3/29 Bio on the Bay with CLSA, San Francisco  Register Here
3/29 The Science of a Startup: Applying the Scientific Method to Start a Biotech Business, UCSF Mission Bay Register Here
4/3 How to Develop, Communicate, and Deliver on a Winning Medtech Strategy, UCSF Mission Bay  Register Here
4/10 Meet with Illumina Accelerator and Illumina Ventures, JLabs, South San Francisco  Register Here
4/10 Fellows & FAST Networking Happy Hour, San Francisco Register Here
4/11 Berkeley IPIRA NSF SBIR Workshop, UC Berkeley Register Here
4/12 Be part of the CaringCrowd – Learn how to get your public health project funded, JLabs, South San Francisco Register Here
4/15 DSM 2018 Health & Human Nutrition Innovation Conference, San Francisco, CA  Register Here
4/17 IndieBio Demo Day, San Francisco, CA  Register Here
4/19 Deadline to apply to be selected as a 2018 Rosenman Innovator  More Info
4/19 Meet with Broadview Ventures, JLabs, South San Francisco Register Here
4/23 Stanford Drug Discovery Conference Register Here
4/24 New Investors, Valuations and Recent Exits for Diagnostics Companies, UCSF Mission Bay Register Here
5/9 JLabs Spotlight Science Fair at Stanford – Bringing it back to basics, Stanford, CA  Register Here
5/10 Meet with 5AM Ventures, JLabs, South San Francisco Register Here
6/1 Submission Deadline for JLabs Mobile Wellness Management QuickFire Challenge Apply Here
6/5 Meet with Pappas Capital, JLabs, South San Francisco Register Here
6/15 Submission Deadline for JLabs European Innovation QuickFire Challenge  Apply Here
6/20 5th Annual Rosenman Symposium, UCSF Mission Bay Register Here



  • CARB-X announced its 2018 rounds of funding to support research into the development of antibiotics, vaccines, diagnostics, devices, and other life-saving products to respond to the threat of drug-resistant bacteria | Read More
  • Powered by CARB-X company, Debiopharm Group announced an investment in antibiotic development with acquisition of ABAC Therapeutics | Read More
  • CARB-X awards up to $4.0 million to Curza to develop a new class of antibiotics to treat a broad spectrum of life-threatening Gram-negative bacteria that are resistant to existing antibiotics | Read More
  • CARB-X awards up to $6.8 million to Macrolide Pharmaceuticals to develop novel macrolide antibiotics with gram negative activity to treat drug-resistant complicated urinary tract infections | Read More
  • CARB-X awards up to $5.2 million to Bay Area’s MicuRx Pharmaceuticals for the early development of a polymyxin antibiotic MRX-8 to treat multi-drug resistant Gram-negative superbugs | Read More
  • CARB-X awards up to $2.0 million to T2 Biosystems for the development of new magnetic resonance tests to quickly diagnose drug-resistant infections in whole blood | Read More

Other AMR News

  • Wellcome Trust released an RFP to develop a business plan for a sustainable clinical trial network for antibiotic development | More Info
  • Novo Holdings announced the launch of the $165 million REPAIR Impact Fund, commissioned by Novo Nordisk Foundation, to invest in companies involved in discovering and early-stage development of therapies to combat antimicrobial resistance. First call for applications begins April 1 and is open to companies in Europe and Israel. Call for applications from US-based companies is expected this fall. | Read More
  • For more information on CARB-X, please contact Heather Shane, or Amy Xu, axu@califesciences.orgScientists at the University of Leeds are re-examining previously discarded chemical compounds by applying advances in science and technology to test more precisely to see if they could be developed for new antibiotics | Read More

 About CARB-X

CARB-X is one of the world's largest public-private partnership devoted to early stage antibacterial R&D. Funded by ASPR/BARDA and Wellcome Trust, with in-kind support from NIAID, CARB-X is investing up to $455 million from 2016-2021 to support innovative products from ‘hit-to-lead’ phase through to Phase 1 clinical trials. CARB-X focuses on high priority drug-resistant bacteria, especially Gram-negatives. CARB-X operates through Boston University. Other partners include RTI International, the Broad Institute of Harvard and MIT, MassBio, and the California Life Sciences Institute (CLSI).

Upcoming Events
3/19 Superbugs and Superdrugs 2018 Register Here
3/29 CARB-X Information Session & Networking with Kevin Outterson and CLSI, San Francisco Register Here
4/6 4/6 Deadline to submit product profiles to participate in Exploring the Antibiotic Pipeline Symposium at IDWeek 2018 (in San Francisco this October). Preference for compounds that are in clinical development, focusing on novel mechanisms and approaches, but not yet approved by FDA. For more details, contact  
4/21 28th European Congress of Clinical Microbiology and Infectious Diseases, Madrid, Spain  Register Here
5/28 Countering Antimicrobial Resistance, Beijing, China Register Here
6/7 ASM Microbe, Atlanta Register Here
9/20 ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, Lisbon, Portugal Register Here

 STEM Education & Careers 

  • CLSI Supports Mission Bay Career Day | Read More
  • Biotech Primer Article: Market Access and Reimbursement Primer | Read More
  • Biotech Primer Article: From Drug Development to Approval: A Recap | Read More
  • Biotech Primer Article: Who’s Your Daddy? The Science of 23andMe | Read More

About CLSI Education & Career Programs

CLSI helps build the next generation of life science professionals by bringing industry and institutions of learning together to improve STEM education in California and to inspire and develop life science careers. CLSI also works to ensure that the current and anticipated talent needs of the industry are met, and that the workforce pipeline for the industry remains strong.

Upcoming Events
3/13 SFSU MBA Information Session Webinar for Biotech Professionals More Info
3/16 Linton-Poodry SACNAS Leadership Institute for postdocs and professionals promotes diverse perspectives in STEM - Deadline to apply More Info
3/22 Deadline EXTENDED to submit application for BioGENEius (April 26, 2018), South San Francisco, CA More Info
3/20 SFSU MBA Information Session Lunch & Learn for Biotech Professionals More Info
4/4 Biomedical and Bioscience Industry Expo (BBIE), Stanford University More Info
4/18 SFSU MBA Information Session Lunch & Learn for Biotech Professionals More Info
5/7 2018 ARCS Symposium Meet the Minds of the Future More Info
5/16 SFSU MBA Information Session Lunch & Learn for Biotech Professionals More Info


California Life Sciences Institute (CLSI) supports the foundations of innovation that have made California home to the world’s most prominent life sciences ecosystem. Our mission is to maintain California’s leadership in life sciences innovation through support of entrepreneurship, education and career development. CLSI also serves as an accelerator for CARB-X, the world’s largest public-private partnership devoted to early stage antibacterial R&D.

CLSI is an affiliate of the California Life Sciences Association (CLSA), which represents California’s leading life sciences organizations. The California Life Sciences Institute is a non-profit 501(c)(3), and was established in 1990 as the BayBio Institute.